Weiss Multi Strategy Advisers LLC Ascendis Pharma A/S Transaction History

Weiss Multi Strategy Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $156,316 - $235,455	-2,002 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $308,277 - $409,557	-3,017 Reduced 60.11%	2,002 $235,000
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $637,914 - $851,523	5,019 New	5,019 $675,000
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $1.89 Million - $2.97 Million	-16,793 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $1.19 Million - $1.43 Million	9,809 Added 140.45%	16,793 $2.21 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $120,672 - $167,436	966 Added 16.05%	6,984 $900,000
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $626,724 - $757,540	-4,145 Reduced 40.79%	6,018 $1 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $15,309 - $17,592	114 Added 1.13%	10,163 $1.57 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $580,293 - $816,556	5,234 Added 108.7%	10,049 $1.49 Million
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $17,946 - $26,845	-185 Reduced 3.7%	4,815 $542,000
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $457,250 - $695,600	5,000 New	5,000 $696,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.